Biophytis S.A. (BPTS)

NASDAQ: BPTS · IEX Real-Time Price · USD
4.70 -0.20 (-4.08%)
Jan 14, 2022 4:00 PM EST - Market closed
Market Cap67.38M
Revenue (ttm)n/a
Net Income (ttm)-25.52M
Shares Out14.34M
EPS (ttm)-3.00
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume301
Open4.70
Previous Close4.90
Day's Range4.70 - 4.70
52-Week Range4.61 - 18.50
Beta1.07
Analystsn/a
Price Targetn/a
Earnings Daten/a

About BPTS

Biophytis SA, a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases and the treatment of severe respiratory failure in patients suffering from COVID-19. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead ...

IndustryBiotechnology
IPO DateFeb 10, 2021
CEOStanislas Veillet
Employees24
Stock ExchangeNASDAQ
Ticker SymbolBPTS
Full Company Profile

Financial Performance

Financial numbers in millions EURFinancial Statements

News

Biophytis Announces the Drawing of the Last Tranche of ORNANE Under the 2020 Atlas Contract for €3 Million

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / December 22, 2021 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS), a clinical-stage biotechnology company focused on the development of therapeut...

3 weeks ago - Accesswire

Biophytis to Meet with FDA to Advance Sarconeos (BIO101) Development in Sarcopenia from Phase 2 to Phase 3

Following Phase2b/SARA-INT clinically meaningful results, Biophytis is starting first regulatory activities to advance from Phase 2 to Phase 3 development A Type B/End-of-Phase 2 meeting is planned with...

1 month ago - Accesswire

Biophytis Obtains a New 10M€ Loan Structure With Kreos Capital

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / November 22, 2021 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris: ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused...

1 month ago - Accesswire

Biophytis To Restart Recruitment In US Centers For COVID-19 Trial

Biophytis SA (NASDAQ: BPTS) has announced that patient recruitment in the U.S., paused in May while waiting for results of the Interim Analysis 2, has restarted.  The Data Monitoring Committee (DMC) had...

2 months ago - Benzinga

Biophytis Announces US Centers to Restart Recruitment for the COVA Phase 2-3 Study with Sarconeos (BIO101) in COVID-19

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / November 15, 2021 / Biophytis SA (NasdaqCM:BPTS, Euronext Growth Paris: ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focus...

2 months ago - Accesswire

Biophytis to Report Restated Financial Statements for Previous Periods and as of June 30, 2021

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / October 29, 2021 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused o...

2 months ago - Accesswire

Biophytis to Restate Previously Issued Financial Statements

PARIS and CAMBRIDGE, Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS) (the “Company” or “Biophytis”), a clinical-stage biotechnology company focused o...

3 months ago - GlobeNewsWire

Biophytis to Host Virtual KOL Event on Sarconeos (BIO101) on its Lead Projects in COVID-19 and Sarcopenia

PARIS and CAMBRIDGE, Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeuti...

3 months ago - GlobeNewsWire

Biophytis Announces the Drawing of 2 New Tranches of ORNANE Under the 2020 Atlas Contract for €6 Million

PARIS and CAMBRIDGE, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeuti...

3 months ago - GlobeNewsWire

Biophytis Announces Promising Full Results From the SARA-INT Phase 2b Trial of Sarconeos (BIO101) in Sarcopenia at th...

PARIS and CAMBRIDGE, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeuti...

3 months ago - GlobeNewsWire

Biophytis to Present Full Results From the SARA-INT Phase 2b Trial of Sarconeos (BIO101) in Sarcopenia at the 11th An...

PARIS and CAMBRIDGE, Mass., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeut...

3 months ago - GlobeNewsWire

Biophytis Reports H1 2021 Financial Results and Provides Business Update

PARIS and CAMBRIDGE, Mass., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeut...

3 months ago - GlobeNewsWire

Biophytis Announces DMC Second Interim Analysis Efficacy Results in the Promising Zone Allowing Continuation of Phase...

PARIS and CAMBRIDGE, Mass., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeut...

4 months ago - GlobeNewsWire

Biophytis to Attend Key Upcoming Investor Events and Industry Conferences

PARIS and CAMBRIDGE, Mass., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeut...

4 months ago - GlobeNewsWire

Biophytis Leadership is Reinforced With New Chief Medical Officer Appointment

PARIS and CAMBRIDGE, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeut...

4 months ago - GlobeNewsWire

DMC Recommends Biophytis Continue Sarconeos COVID-19 Study

The Data Monitoring Committee (DMC) has recommended Biophytis SA (NASDAQ: BPTS) to continue patient recruitment into part 2 of Phase 2-3 COVA Study in COVID-19, with the protocol unmodified after review...

4 months ago - Benzinga

Biophytis Receives Favorable Recommendation From Data Monitoring Committee (DMC) Based on Safety Analysis of Sarconeo...

PARIS and CAMBRIDGE, Mass., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeuti...

5 months ago - GlobeNewsWire

Biophytis Announces the Issue of 4,950,000 New Shares in a Capital Increase Reserved for NEGMA and the Performance of...

PARIS and CAMBRIDGE, Mass., Aug. 13, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “company”), a clinical-stage biotechnology company focused ...

5 months ago - GlobeNewsWire

Biophytis Stock Gains As Sarconeos High Dose Improves Gait Speed Versus Placebo In Patients With Muscle Loss Due To A...

Biophytis SA (NASDAQ: BPTS) has announced top-line results of the SARA-INT phase 2 clinical study with Sarconeos (BIO101) in sarcopenia patients. Sarcopenia is a condition characterized by loss of skele...

5 months ago - Benzinga

Biophytis Announces Top Line Results of SARA-INT Phase 2 Study With Sarconeos (BIO101) in Sarcopenia

PARIS and CAMBRIDGE, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “company”) is a clinical-stage biotechnology company focuse...

5 months ago - GlobeNewsWire

Judgment Rendered on July 16, 2021 in the Proceedings Between Biophytis and Negma Group Ltd by the Execution Judge Fr...

PARIS and CAMBRIDGE, Mass., July 19, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company focused ...

5 months ago - GlobeNewsWire

Biophytis Stock Is Trading Higher On Encouraging Preclinical Data From COVID-19 Study With Sarconeos

Biophytis SA (NASDAQ: BPTS) announced new positive preclinical data on Sarconeos (BIO101) in hamsters infected with SARS-CoV-2, the virus responsible for COVID-19. The data will be presented at the Euro...

6 months ago - Benzinga

Biophytis Presents Positive Preclinical Data on Sarconeos (BIO101) in COVID-19 at ECCMID 2021

PARIS and CAMBRIDGE, Mass., July 12, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “company”), a clinical-stage biotechnology company focused...

6 months ago - GlobeNewsWire

Biophytis Reinforces Leadership Teams with Three Senior Appointments

PARIS and CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “company”), a clinical-stage biotechnology company focused...

6 months ago - GlobeNewsWire

Biophytis Secures the Manufacturing of Sarconeos (BIO101) for COVID-19 with a Global CDMO & Announces the Next Milest...

PARIS and CAMBRIDGE Mass., June 30, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “company”), a clinical-stage biotechnology company focused ...

6 months ago - GlobeNewsWire